Bayer Decides Against Splitting Up Company For Now
Provided by
Dow Jones
By Dominic Chopping
Bayer won't break up the company into separate units just yet, Chief Executive Bill Anderson said.
"On the question of the company's structure and a possible break-up of the group, our answer is 'not now'--and this shouldn't be misunderstood as 'never'," Anderson said Tuesday.
The German pharmaceutical and agricultural conglomerate has been looking into various options for the group as it seeks to cut debt and boost its beleaguered share price.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
March 05, 2024 02:06 ET (07:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?